Fate Therapeutics
Skip to content
  • About Us
    • Our Mission
    • Our Cells of Interest
    • Management
    • Board of Directors
    • Corporate Responsibility
  • Pipeline
    • Overview
    • Product Candidates
      • FT576
      • FT522
      • FT819
      • FT825
    • Early/Expanded Access Policy
  • Science
    • iPSC Platform
    • Manufacturing
    • Publications
  • Collaborations
  • Working at Fate
    • The Fate Way
    • Join Our Team
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historical Stock Lookup
    • Investors FAQs
  • Contact
  • About Us
    • Our Mission
    • Our Cells of Interest
    • Management
    • Board of Directors
    • Corporate Responsibility
  • Pipeline
    • Overview
    • Product Candidates
      • FT576
      • FT522
      • FT819
      • FT825
    • Early/Expanded Access Policy
  • Science
    • iPSC Platform
    • Manufacturing
    • Publications
  • Collaborations
  • Working at Fate
    • The Fate Way
    • Join Our Team
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historical Stock Lookup
    • Investors FAQs
  • Contact
2022 ASH Poster Presentation, Publications

High-Density Cryopreservation of Off-the-Shelf CAR Cells Facilitates On-demand Treatment Access

2022 ASH Poster Presentation, Publications

Alloimmune Defense Receptor Redirects Host Immune Cell Alloreactivity to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf Cell-Based Cancer Therapy

2022 ASH Poster Presentation, Publications

A CD3 Fusion Receptor (CD3-FR) Uniquely Enables Compatibility of Allogeneic CAR-T and -NK cells with T Cell Engagers to Enhance Antitumor Function and Limit Antigen Escape

2022 ASH Poster Presentation, Publications

Off-the-Shelf CAR-NK cell Therapy co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma

2022 ASH Poster Presentation, Publications

CD82 Is Sufficient to Uniquely Identify Pluripotent Stem Cell-Derived Hemogenic Endothelium With the Hematopoietic Lineage Potency to Give Rise To Bona Fide Lymphocytes

2022 ASH Poster Presentation, Publications

iPSC-derived CD38-null NK Cells in Combination with CD38-targeted Antibody: a Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma

2022 ASH Poster Presentation, Publications

Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection

2022 ASH Poster Presentation, Publications

Characterization of Engineered Macrophages and other Myeloid Cells Differentiated from CD34+ Hematopoietic Progenitor Cells Derived from Pluripotent Stem Cells

2022 ASH Poster Presentation, Publications

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogeneous Population Associated with AML

2022 ASH Poster Presentation

2022 ASH Poster Presentation, Publications

Multi-Antigen Targeting by Novel Combination of CAR-T Cells and hnCD16 Transgene Yields in Complete Tumor Clearance via Antibody Dependent Cellular Cytotoxicity

2022 ASH Poster Presentation

2022 ASH Poster Presentation, Publications

The Development of Allogeneic Tips-Derived TCR- CAR+ CD8⍺β T Cells

©2023 Fate Therapeutics | 12278 Scripps Summit Drive, San Diego, CA 92131 | 866.875.1833 | LEGAL | PRIVACY

MENU
  • About Us
    • Our Mission
    • Our Cells of Interest
    • Management
    • Board of Directors
    • Corporate Responsibility
  • Pipeline
    • Overview
    • Product Candidates
      • FT576
      • FT522
      • FT819
      • FT825
    • Early/Expanded Access Policy
  • Science
    • iPSC Platform
    • Manufacturing
    • Publications
  • Collaborations
  • Working at Fate
    • The Fate Way
    • Join Our Team
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historical Stock Lookup
    • Investors FAQs
  • Contact

We are using cookies to give you the best experience on our website. To find out more about the information we collect please visit our Privacy Policy

You can find out more about which cookies we are using or switch them off in settings.

Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

For more information about the data we collect please visit our Privacy Policy.

Strictly Necessary Cookies

Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!